<DOC>
	<DOCNO>NCT03061032</DOCNO>
	<brief_summary>Hepatitis C virus ( HCV ) infection around 0.5 % 2.2 % prevalence Iran world one public health problem result chronic liver disease , cirrhosis hepatocellular carcinoma . All case chronic HCV infection candidate treatment prevent advance liver disease . The previous Pegylated-interferon Ribavirin therapy efficient case result numerous number side-effects . Introduction direct act antiviral agent ( DAAs ) Sofosbuvir Ledipasvir make eradication HCV possible however regimens affordable available develop country . The generic DAAs manufacture many country Iran provide treatment reasonable price .</brief_summary>
	<brief_title>Treatment Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir Iranian Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Chronic HCV infection &gt; 18 year old HIV coinfected Liver transplant Receiving drug suspect interaction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>